MCID: GLL017
MIFTS: 45

Gallbladder Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gallbladder Adenocarcinoma

MalaCards integrated aliases for Gallbladder Adenocarcinoma:

Name: Gallbladder Adenocarcinoma 12 15 73
Adenocarcinoma of the Gallbladder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3500
NCIt 50 C9166
UMLS 73 C0279651

Summaries for Gallbladder Adenocarcinoma

Disease Ontology : 12 A gallbladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Gallbladder Adenocarcinoma, also known as adenocarcinoma of the gallbladder, is related to papillary adenocarcinoma and mucinous adenocarcinoma, and has symptoms including abdominal pain An important gene associated with Gallbladder Adenocarcinoma is MUC2 (Mucin 2, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are G-protein signaling RAC1 in cellular process and Signaling by ERBB2. The drugs Oxaliplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and lymph node, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Related Diseases for Gallbladder Adenocarcinoma

Diseases related to Gallbladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Related Disease Score Top Affiliating Genes
1 papillary adenocarcinoma 30.2 ERBB2 MUC2
2 mucinous adenocarcinoma 30.1 EGFR MUC2
3 gallbladder cancer 29.9 EGFR ERBB2 MUC2
4 cholangiocarcinoma 29.8 EGFR ERBB2 MUC2
5 adenocarcinoma of the gallbladder and extrahepatic biliary tract 12.3
6 gallbladder pleomorphic giant cell adenocarcinoma 11.2
7 adenocarcinoma 10.8
8 hepatoid adenocarcinoma 10.3
9 breast intraductal proliferative lesion 10.2 EGFR ERBB2
10 progesterone-receptor negative breast cancer 10.2 EGFR ERBB2
11 breast scirrhous carcinoma 10.2 EGFR ERBB2
12 breast squamous cell carcinoma 10.2 EGFR ERBB2
13 microglandular adenosis 10.2 EGFR ERBB2
14 inflammatory breast carcinoma 10.2 EGFR ERBB2
15 luminal breast carcinoma 10.2 EGFR ERBB2
16 acneiform dermatitis 10.2 EGFR ERBB2
17 lipid-rich carcinoma 10.2 EGFR ERBB2
18 mucinous lung adenocarcinoma 10.2 EGFR ERBB2
19 mammary paget's disease 10.2 EGFR ERBB2
20 primary peritoneal carcinoma 10.2 EGFR ERBB2
21 tuberculous salpingitis 10.2 ERBB2 MYB
22 adenosquamous lung carcinoma 10.2 EGFR ERBB2
23 tubular adenocarcinoma 10.1 ERBB2 MUC2
24 pre-malignant neoplasm 10.1 EGFR ERBB2
25 hidradenocarcinoma 10.1 EGFR ERBB2 MUC2
26 stomach disease 10.1 EGFR ERBB2 MUC2
27 mucoepidermoid carcinoma 10.1 EGFR ERBB2 MUC2
28 cholecystitis 10.1
29 gastrointestinal system disease 10.1 EGFR ERBB2 MUC2
30 large cell neuroendocrine carcinoma 10.1
31 xanthogranulomatous cholecystitis 10.0
32 glioblastoma multiforme 10.0 EGFR ERBB2 MTDH
33 signet ring cell adenocarcinoma 10.0 MUC2 SRC
34 bronchiolo-alveolar adenocarcinoma 10.0 EGFR MUC2
35 acanthosis nigricans 10.0
36 small cell carcinoma 10.0
37 exanthem 10.0 EGFR ERBB2
38 in situ pulmonary adenocarcinoma 9.9 EGFR PROM1
39 drug-induced lupus erythematosus 9.9 MCAM PROM1
40 gastric adenosquamous carcinoma 9.9 PROM1 SRC
41 laryngeal disease 9.9 EGFR PROM1
42 bladder cancer 9.9 EGFR ERBB2 MUC2 SRC
43 hepatocellular carcinoma 9.8
44 osteogenic sarcoma 9.8
45 bile duct cysts 9.8
46 acute interstitial pneumonia 9.8
47 clear cell adenocarcinoma 9.8
48 bile duct cancer 9.8
49 pneumonia 9.8
50 lymphoepithelioma-like carcinoma 9.8

Graphical network of the top 20 diseases related to Gallbladder Adenocarcinoma:



Diseases related to Gallbladder Adenocarcinoma

Symptoms & Phenotypes for Gallbladder Adenocarcinoma

UMLS symptoms related to Gallbladder Adenocarcinoma:


abdominal pain

GenomeRNAi Phenotypes related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 EGFR ERBB2 SRC
2 Decreased viability with paclitaxel GR00179-A-3 8.92 EGFR

MGI Mouse Phenotypes related to Gallbladder Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.8 EGFR ERBB2 MCAM MTDH MUC2 MYB
2 hematopoietic system MP:0005397 9.7 EGFR MCAM MTDH MUC2 MYB SLC29A1
3 neoplasm MP:0002006 9.43 EGFR ERBB2 MTDH MUC2 PROM1 SRC
4 no phenotypic analysis MP:0003012 9.02 EGFR MCAM MYB PROM1 SLC29A1

Drugs & Therapeutics for Gallbladder Adenocarcinoma

Drugs for Gallbladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
4 Immunologic Factors Phase 3,Phase 2,Phase 1
5 Anti-Infective Agents Phase 3,Phase 2,Phase 1
6 Liver Extracts Phase 3,Phase 2,Phase 1
7 Antiviral Agents Phase 3,Phase 2,Phase 1
8 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
9 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
10 Antimetabolites Phase 3,Phase 2,Phase 1
11
Bevacizumab Approved, Investigational Phase 2 216974-75-3
12
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
13
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
14
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
15
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
16
Pancrelipase Approved, Investigational Phase 2,Phase 1 53608-75-6
17
Melphalan Approved Phase 2 148-82-3 4053 460612
18
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
19
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
21 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
22 Angiogenesis Inhibitors Phase 2
23 Angiogenesis Modulating Agents Phase 2
24 Vitamin B Complex Phase 2,Phase 1
25 Vitamin B9 Phase 2,Phase 1
26 Trace Elements Phase 2,Phase 1
27 Nicotinic Acids Phase 2
28 Vitamins Phase 2,Phase 1
29 Micronutrients Phase 2,Phase 1
30 Vitamin B3 Phase 2
31
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
32 Folate Phase 2,Phase 1
33 Protein Kinase Inhibitors Phase 2,Phase 1
34 Antineoplastic Agents, Alkylating Phase 2
35 Alkylating Agents Phase 2
36 Cola Phase 2,Phase 1
37 pancreatin Phase 2,Phase 1
38 Vaccines Phase 2,Phase 1
39 Freund's Adjuvant Phase 2
40 Adjuvants, Immunologic Phase 2
41
Cisplatin Approved Phase 1 15663-27-1 2767 441203 84093
42
Metronidazole Approved Phase 1 443-48-1 4173
43
Atezolizumab Approved, Investigational Phase 1 1380723-44-3
44
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
45
Levoleucovorin Approved, Investigational Phase 1 68538-85-2
46
Irinotecan Approved, Investigational Phase 1 100286-90-6, 97682-44-5 60838
47
leucovorin Approved Phase 1 58-05-9 6006 143
48
Fluorouracil Approved Phase 1 51-21-8 3385
49
Camptothecin Experimental Phase 1 7689-03-4
50 Antiparasitic Agents Phase 1

Interventional clinical trials:

(show all 29)
# Name Status NCT ID Phase Drugs
1 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
2 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
3 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
4 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
5 Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer Completed NCT00142480 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
6 Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer Completed NCT00361231 Phase 2 Bevacizumab;Gemcitabine;Oxaliplatin
7 A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts Completed NCT01007552 Phase 2 Gemcitabine, Capecitabine and Bevacizumab
8 A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC Completed NCT01267344 Phase 2 gemcitabine, oxaliplatin;cetuximab, gemcitabine, oxaliplatin
9 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
10 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Completed NCT00478140 Phase 2
11 S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
12 Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer Completed NCT00073905 Phase 2 capecitabine plus gemcitabine
13 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
14 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
15 Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder Terminated NCT00085410 Phase 2 bortezomib
16 Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract Terminated NCT00012246 Phase 2
17 Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery Withdrawn NCT01859182 Phase 2 selumetinib;Akt inhibitor MK2206
18 ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery Completed NCT01825603 Phase 1 ADH-1;Cisplatin;Gemcitabine Hydrochloride
19 Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Completed NCT00028496 Phase 1
20 Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer Completed NCT00544193 Phase 1 gemcitabine hydrochloride
21 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
22 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
23 Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer Completed NCT00266097 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin;gemcitabine hydrochloride;Oxaliplatin
24 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
25 Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer Completed NCT00027534 Phase 1
26 Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab, CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma Recruiting NCT03267940 Phase 1 PEGPH20;CIS;GEM;Atezolizumab
27 Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Recruiting NCT03257761 Phase 1 Guadecitabine
28 Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Active, not recruiting NCT01643499 Phase 1 oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil
29 Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder Completed NCT00489515

Search NIH Clinical Center for Gallbladder Adenocarcinoma

Genetic Tests for Gallbladder Adenocarcinoma

Anatomical Context for Gallbladder Adenocarcinoma

MalaCards organs/tissues related to Gallbladder Adenocarcinoma:

41
Liver, T Cells, Lymph Node, Skin, Lung, Pancreas, B Cells

Publications for Gallbladder Adenocarcinoma

Articles related to Gallbladder Adenocarcinoma:

(show top 50) (show all 141)
# Title Authors Year
1
Contrast-enhanced ultrasound findings of gallbladder adenocarcinoma with sarcomatoid carcinoma accompanied by intrahepatic metastasis: A case report and literature review. ( 29794755 )
2018
2
Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy. ( 29069888 )
2018
3
Simultaneous osteosarcoma and adenocarcinoma of the gallbladder: A rare case report and literature review. ( 30460899 )
2018
4
18F-FDG PET/CT in detection of occult gallbladder adenocarcinoma presenting as bilateral ovarian Krukenberg tumors. ( 30366729 )
2018
5
A predictive model for survival of gallbladder adenocarcinoma. ( 30217289 )
2018
6
Elevated Vitamin B12: A Rare Presentation for Gallbladder Adenocarcinoma. ( 29996035 )
2018
7
Gallbladder adenocarcinoma diagnosed from cutaneous metastases occurring along the tract of a ventriculoperitoneal shunt. ( 30054926 )
2018
8
Metastasis of gallbladder adenocarcinoma to the skin of the external auditory canal, a case report. ( 28522135 )
2017
9
Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation. ( 28785956 )
2017
10
Decision of surgical approach for advanced gallbladder adenocarcinoma based on a Bayesian network. ( 28876457 )
2017
11
Spontaneous cholecystocutaneous fistula as a primary manifestation of gallbladder adenocarcinoma associated with gallbladder lithiasis - case report. ( 28730246 )
2017
12
Cytokeratin 17 Expression is Associated With Poor Prognosis in Gallbladder Adenocarcinoma. ( 26990743 )
2016
13
Breast metastasis from recurrent gallbladder adenocarcinoma: a case report with review of the literature. ( 27512606 )
2016
14
Diffusion-weighted magnetic resonance imaging of gallbladder adenocarcinoma: analysis with emphasis on histologic grade. ( 27133665 )
2016
15
Gallbladder adenocarcinoma and paraneoplastic parathyroid hormone mediated hypercalcemia. ( 27081650 )
2016
16
Immunohistochemical expression of mucin antigens in gallbladder adenocarcinoma: MUC1-positive and MUC2-negative expression Is associated with vessel invasion and shortened survival. ( 27672051 )
2016
17
A case of neuroendocrine carcinoma in the hepatic hilar lymph nodes concomitant with an adenocarcinoma of the gallbladder. ( 27842605 )
2016
18
BRMS1 and HPA as Progression, Clinical Biological Behaviors, and Poor Prognosis-related Biomarkers for Gallbladder Adenocarcinoma. ( 26200836 )
2015
19
Dermatomyositis as the first manifestation of gallbladder adenocarcinoma: case report and literature overview. ( 25890241 )
2015
20
Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naA^ve pT2 gallbladder adenocarcinoma patients. ( 26266900 )
2015
21
Gallbladder neuroendocrine carcinoma: report of 10 cases and comparision of clinicopathologic features with gallbladder adenocarcinoma. ( 26339390 )
2015
22
Surgical resection of solid gallbladder adenocarcinoma presenting as a large mass: report of a case. ( 25884804 )
2015
23
18F-FDG PET/CT Imaging of Gallbladder Adenocarcinoma - A Pictorial Review. ( 26430572 )
2015
24
Exfoliative erythroderma as a paraneoplastic presentation of adenocarcinoma of the gallbladder. ( 25830047 )
2015
25
Adenocarcinoma of the Gallbladder: Incidental Finding in Patients following Laparoscopic Sleeve Gastrectomy and Cholecystectomy. ( 26757568 )
2015
26
Histological phenotype is correlated with the wall-invasion pattern of gallbladder adenocarcinoma. ( 25355436 )
2014
27
Gallbladder adenocarcinoma with sarcoid-like reaction in regional lymph nodes: report of a case. ( 25495692 )
2014
28
Vitamin D receptor genetic variants are associated with susceptibility of gallbladder adenocarcinoma in a Chinese cohort. ( 25078595 )
2014
29
Lymph node status after resection for gallbladder adenocarcinoma: Prognostic implications of different nodal staging/scoring systems. ( 25312786 )
2014
30
Overexpression of MTA1 and loss of KAI-1 and KiSS-1 expressions are associated with invasion, metastasis, and poor-prognosis of gallbladder adenocarcinoma. ( 25688501 )
2014
31
Re: metastasis of gallbladder adenocarcinoma to Bauhin's valve: an extremely rare cause of intestinal obstruction. ( 25246829 )
2014
32
Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma. ( 26176038 )
2014
33
Combined hepato-cholangiocarcinoma arising in a gallbladder intracystic papillary neoplasm. A new view on so-called "hepatoid adenocarcinoma of the gallbladder". ( 24897774 )
2014
34
TSG101 and PEG10 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of the gallbladder. ( 24944680 )
2014
35
Histopathological and immunophenotypical features of intestinal-type adenocarcinoma of the gallbladder and its precursors. ( 24955710 )
2014
36
Coexistence of xanthogranulomatous cholecystitis and gallbladder adenocarcinoma: a fortuitous association? ( 24471194 )
2013
37
Gastrointestinal Stromal Tumor with Synchronous Gallbladder Adenocarcinoma. ( 23749654 )
2013
38
Secondary Sclerosing Cholangitis due to Gallbladder Adenocarcinoma. ( 23626514 )
2013
39
Clinicopathological features and CCT2 and PDIA2 expression in gallbladder squamous/adenosquamous carcinoma and gallbladder adenocarcinoma. ( 23782473 )
2013
40
Antiproliferative and apoptosis-inducing activity of curcumin against human gallbladder adenocarcinoma cells. ( 23645731 )
2013
41
Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma. ( 23544944 )
2013
42
Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: A propensity score-matched Surveillance, Epidemiology, and End Results analysis. ( 23876364 )
2013
43
Cheek metastasis from gallbladder adenocarcinoma. ( 23669176 )
2013
44
Cutaneous metastasis of gallbladder adenocarcinoma in a patient with chronic lymphocytic leukemia: a case report and review of the literature. ( 23467457 )
2013
45
Expression of Cell Cycle-Related Proteins, p16, p53 and p63 as Important Prognostic Markers in Gallbladder Adenocarcinoma. ( 24178677 )
2013
46
Expression of p53 upregulated modulator of apoptosis (PUMA) and C-myb in gallbladder adenocarcinoma and their pathological significance. ( 23475628 )
2013
47
Correlation of S1P1 and ERp29 expression to progression, metastasis, and poor prognosis of gallbladder adenocarcinoma. ( 23558074 )
2013
48
MTDH and EphA7 are markers for metastasis and poor prognosis of gallbladder adenocarcinoma. ( 21964981 )
2013
49
PSCA and Oct-4 expression in the benign and malignant lesions of gallbladder: implication for carcinogenesis, progression, and prognosis of gallbladder adenocarcinoma. ( 23984394 )
2013
50
Diagnostic utility of von Hippel-Lindau gene product, maspin, IMP3, and S100P in adenocarcinoma of the gallbladder. ( 23079206 )
2013

Variations for Gallbladder Adenocarcinoma

Expression for Gallbladder Adenocarcinoma

Search GEO for disease gene expression data for Gallbladder Adenocarcinoma.

Pathways for Gallbladder Adenocarcinoma

Pathways related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.13 EGFR EPHA7 ERBB2 SRC
2
Show member pathways
12.09 EGFR ERBB2 SRC
3 12.06 EGFR ERBB2 SRC
4
Show member pathways
11.98 EGFR MUC2 SRC
5 11.94 EGFR ERBB2 SRC
6
Show member pathways
11.88 EGFR ERBB2 SRC
7
Show member pathways
11.84 EGFR ERBB2 SRC
8
Show member pathways
11.73 EGFR ERBB2 SRC
9 11.44 EGFR ERBB2 SRC
10 11.43 EGFR EPHA7 ERBB2 SRC
11 11.4 EGFR ERBB2 SRC
12 11.33 EGFR ERBB2 SRC
13
Show member pathways
11.3 EGFR ERBB2 SRC
14 11.19 EGFR ERBB2 SRC
15 11.14 EGFR SRC
16 11.14 EGFR SRC
17 11.12 EGFR MTDH
18 11.08 EGFR ERBB2
19 10.99 EGFR ERBB2 SRC
20 10.97 EGFR SRC
21 10.79 EGFR SRC
22 10.71 EGFR SRC
23 10.28 EGFR ERBB2 PROM1

GO Terms for Gallbladder Adenocarcinoma

Cellular components related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.62 EGFR ERBB2 MTDH SRC
2 receptor complex GO:0043235 9.33 EGFR EPHA7 ERBB2
3 basal plasma membrane GO:0009925 9.26 EGFR ERBB2
4 basolateral plasma membrane GO:0016323 9.13 EGFR ERBB2 SLC29A1
5 apical plasma membrane GO:0016324 9.02 EGFR ERBB2 MTDH PROM1 SLC29A1

Biological processes related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.89 EGFR EPHA7 ERBB2 SRC
2 negative regulation of apoptotic process GO:0043066 9.77 EGFR EPHA7 ERBB2 MTDH SRC
3 positive regulation of protein phosphorylation GO:0001934 9.72 EGFR EPHA7 ERBB2
4 protein autophosphorylation GO:0046777 9.71 EGFR ERBB2 SRC
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.71 EGFR EPHA7 ERBB2 SRC
6 positive regulation of MAPK cascade GO:0043410 9.69 EGFR EPHA7 ERBB2
7 negative regulation of signal transduction GO:0009968 9.67 EGFR EPHA7 ERBB2
8 phosphatidylinositol phosphorylation GO:0046854 9.65 EGFR ERBB2 SRC
9 cellular response to reactive oxygen species GO:0034614 9.58 EGFR SRC
10 peptidyl-tyrosine autophosphorylation GO:0038083 9.58 EGFR SRC
11 ERBB2 signaling pathway GO:0038128 9.57 EGFR ERBB2
12 regulation of cell motility GO:2000145 9.56 EGFR ERBB2
13 peptidyl-tyrosine phosphorylation GO:0018108 9.56 EGFR EPHA7 ERBB2 SRC
14 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.52 EGFR EPHA7
15 positive regulation of MAP kinase activity GO:0043406 9.5 EGFR ERBB2 SRC
16 regulation of cell-cell adhesion GO:0022407 9.46 EPHA7 SRC
17 positive regulation of protein kinase B signaling GO:0051897 9.46 EGFR ERBB2 MTDH SRC
18 negative regulation of ERBB signaling pathway GO:1901185 9.43 EGFR ERBB2
19 regulation of ERK1 and ERK2 cascade GO:0070372 9.13 EGFR EPHA7 ERBB2
20 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 8.92 EGFR EPHA7 ERBB2 SRC

Molecular functions related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.56 EGFR EPHA7 ERBB2 SRC
2 transmembrane signaling receptor activity GO:0004888 9.54 EGFR EPHA7 ERBB2
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.33 EGFR ERBB2 SRC
4 ephrin receptor binding GO:0046875 9.32 EPHA7 SRC
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR EPHA7 ERBB2
6 protein tyrosine kinase activity GO:0004713 8.92 EGFR EPHA7 ERBB2 SRC

Sources for Gallbladder Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....